MXPA05008397A - Composiciones farmaceuticas que comprenden derivados de tieno[2,3-c]piridina y uso de las mismas. - Google Patents
Composiciones farmaceuticas que comprenden derivados de tieno[2,3-c]piridina y uso de las mismas.Info
- Publication number
- MXPA05008397A MXPA05008397A MXPA05008397A MXPA05008397A MXPA05008397A MX PA05008397 A MXPA05008397 A MX PA05008397A MX PA05008397 A MXPA05008397 A MX PA05008397A MX PA05008397 A MXPA05008397 A MX PA05008397A MX PA05008397 A MXPA05008397 A MX PA05008397A
- Authority
- MX
- Mexico
- Prior art keywords
- thieno
- pyridine derivatives
- pharmaceutical compositions
- gag
- interactions
- Prior art date
Links
- GDQBPBMIAFIRIU-UHFFFAOYSA-N thieno[2,3-c]pyridine Chemical class C1=NC=C2SC=CC2=C1 GDQBPBMIAFIRIU-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229920002683 Glycosaminoglycan Polymers 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 abstract 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL15430603A IL154306A0 (en) | 2003-02-05 | 2003-02-05 | Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof |
| PCT/IL2004/000121 WO2004069149A2 (en) | 2003-02-05 | 2004-02-05 | Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05008397A true MXPA05008397A (es) | 2006-02-17 |
Family
ID=30011984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05008397A MXPA05008397A (es) | 2003-02-05 | 2004-02-05 | Composiciones farmaceuticas que comprenden derivados de tieno[2,3-c]piridina y uso de las mismas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7365080B2 (enExample) |
| EP (1) | EP1589970A4 (enExample) |
| JP (1) | JP2006516610A (enExample) |
| KR (1) | KR20050100655A (enExample) |
| CN (1) | CN1771037A (enExample) |
| AU (1) | AU2004210241A1 (enExample) |
| CA (1) | CA2515102A1 (enExample) |
| IL (1) | IL154306A0 (enExample) |
| MX (1) | MXPA05008397A (enExample) |
| WO (1) | WO2004069149A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060275214A1 (en) * | 2003-12-30 | 2006-12-07 | Rimonyx Pharmaceuticals Ltd. | Methods of screening for anti-inflammatory drugs and use thereof |
| EP1738170A2 (en) * | 2004-03-24 | 2007-01-03 | Rimonyx Pharmaceuticals Ltd. | Screening of anti-viral drugs and pharmaceutical compositions containing thiazolidinone derivatives |
| EA012280B1 (ru) | 2004-05-28 | 2009-08-28 | 4Сц Аг | Новые производные тетрагидропиридотиофена |
| EP1756118B1 (en) | 2004-06-04 | 2008-05-28 | Nycomed GmbH | Tetrahydropyridothiophenes for use in the treatment of cancer |
| WO2005120642A2 (en) * | 2004-06-11 | 2005-12-22 | Altana Pharma Ag | Tetrahydropyridothiophenes for treating hyperproliferative disorders |
| US8338648B2 (en) * | 2004-06-12 | 2012-12-25 | Signum Biosciences, Inc. | Topical compositions and methods for epithelial-related conditions |
| CA2596202A1 (en) | 2005-02-09 | 2006-08-17 | Altana Pharma Ag | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer |
| WO2006084904A1 (en) | 2005-02-11 | 2006-08-17 | Nycomed Gmbh | Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer |
| JP2008542243A (ja) * | 2005-05-25 | 2008-11-27 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規のテトラヒドロピリドチオフェン |
| US7714136B2 (en) | 2005-05-25 | 2010-05-11 | 4Sc Ag | Tetrahydropyridothiophenes |
| US20100298370A1 (en) * | 2006-03-20 | 2010-11-25 | Paul Gregor | Benzothiazolyl thienopyridine derivatives and uses thereof |
| US8466149B2 (en) | 2007-08-15 | 2013-06-18 | Merck Sharp & Dohme Corp. | 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11β-hydroxysteroid dehydrogenase type-I |
| RU2364597C1 (ru) * | 2007-12-14 | 2009-08-20 | Андрей Александрович Иващенко | ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ |
| WO2010003023A2 (en) * | 2008-07-01 | 2010-01-07 | Zacharon Pharmaceuticals, Inc. | Heparan sulfate inhibitors |
| HRP20192147T1 (hr) | 2009-03-02 | 2020-02-21 | Stemsynergy Therapeutics, Inc. | Metode i pripravci za uporabu u liječenju raka i smanjenju wnt posredovanih učinaka u stanici |
| CN102869656B (zh) | 2010-04-28 | 2014-03-12 | 安斯泰来制药株式会社 | 四氢苯并噻吩化合物 |
| WO2012148889A1 (en) * | 2011-04-28 | 2012-11-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of human apurinic/apyrimidinic endonuclease 1 |
| EP3777867A1 (en) * | 2011-11-29 | 2021-02-17 | Gilead Pharmasset LLC | Composition and methods for treating hepatitis c virus |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| CN104829629B (zh) * | 2015-03-26 | 2017-03-15 | 天津药物研究院有限公司 | 含磺酰胺基的四氢噻吩并[2,3‑c]吡啶衍生物、其制备方法和用途 |
| US10787444B2 (en) | 2015-06-05 | 2020-09-29 | Syros Pharmaceuticals, Inc. | Compounds for the modulation of myc activity |
| US10106290B2 (en) | 2015-12-14 | 2018-10-23 | Westrock Shared Services, Llc | Carton, blank, and method of folding |
| WO2017184947A1 (en) * | 2016-04-21 | 2017-10-26 | The University Of Toledo | Anti-infective 2-aminothiophenes |
| WO2017214941A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 一种提升SelP基因表达水平的慢病毒载体及其应用 |
| ES2922932T3 (es) | 2016-12-29 | 2022-09-21 | Enyo Pharma | Derivados de tiofeno como agentes antivirales |
| TWI823085B (zh) | 2017-01-13 | 2023-11-21 | 日商東菱藥品工業股份有限公司 | 嗜中性白血球活化調節劑 |
| WO2021050994A1 (en) * | 2019-09-13 | 2021-03-18 | Aerie Pharmaceuticals, Inc. | Heterobicyclic carboxamides and uses thereof |
| WO2023038876A1 (en) * | 2021-09-07 | 2023-03-16 | Gismo Therapeutics, Inc. | Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interactions with glycosaminoglycans, methods of treatment, and use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002517396A (ja) * | 1998-06-04 | 2002-06-18 | アボット・ラボラトリーズ | 細胞接着阻害抗炎症性化合物 |
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| HK1045306A1 (zh) * | 1999-06-03 | 2002-11-22 | Abbott Laboratories | 抑制细胞黏附的抗炎化合物 |
| JP4548882B2 (ja) * | 1999-11-30 | 2010-09-22 | 興和創薬株式会社 | ４，５，６，７−テトラヒドロチエノ〔２，３−ｃ〕ピリジン化合物 |
-
2003
- 2003-02-05 IL IL15430603A patent/IL154306A0/xx unknown
-
2004
- 2004-02-05 JP JP2006502633A patent/JP2006516610A/ja not_active Ceased
- 2004-02-05 US US10/543,065 patent/US7365080B2/en not_active Expired - Fee Related
- 2004-02-05 MX MXPA05008397A patent/MXPA05008397A/es not_active Application Discontinuation
- 2004-02-05 EP EP04708427A patent/EP1589970A4/en not_active Withdrawn
- 2004-02-05 CN CNA2004800093693A patent/CN1771037A/zh active Pending
- 2004-02-05 KR KR1020057014345A patent/KR20050100655A/ko not_active Withdrawn
- 2004-02-05 CA CA002515102A patent/CA2515102A1/en not_active Abandoned
- 2004-02-05 AU AU2004210241A patent/AU2004210241A1/en not_active Abandoned
- 2004-02-05 WO PCT/IL2004/000121 patent/WO2004069149A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004069149A2 (en) | 2004-08-19 |
| EP1589970A4 (en) | 2008-05-21 |
| IL154306A0 (en) | 2003-09-17 |
| JP2006516610A (ja) | 2006-07-06 |
| US20060135529A1 (en) | 2006-06-22 |
| EP1589970A2 (en) | 2005-11-02 |
| KR20050100655A (ko) | 2005-10-19 |
| CA2515102A1 (en) | 2004-08-19 |
| US7365080B2 (en) | 2008-04-29 |
| WO2004069149A3 (en) | 2004-11-25 |
| AU2004210241A1 (en) | 2004-08-19 |
| CN1771037A (zh) | 2006-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05008397A (es) | Composiciones farmaceuticas que comprenden derivados de tieno[2,3-c]piridina y uso de las mismas. | |
| WO2005046603A3 (en) | Pyridine compounds | |
| NO20070091L (no) | Sukkerbelegg og fremgangsmate for dette | |
| AU2003297684A1 (en) | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders | |
| WO2001064214A3 (en) | Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors | |
| CA2514473A1 (en) | Fused bicyclic nitrogen-containing heterocycles | |
| IL172346A0 (en) | Treatment of t cell mediated diseases by inhibition of fgfr3 | |
| MX2007001638A (es) | Proteinas de fusion del dominio de unión. | |
| WO2004041203A3 (en) | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | |
| NZ542616A (en) | P38 inhibitors and methods of use thereof | |
| MXPA05009015A (es) | Nuevos derivados de bencimidazol e imidazo-piridina y su utilizacion como medicamentos. | |
| AU2003268156A1 (en) | Novel pyrazolopyridine derivatves as pharmaceutical agents | |
| SG179410A1 (en) | Therapeutic uses of inhibitors of rtp801 | |
| TW200510325A (en) | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | |
| AU2002358390A1 (en) | Novel compounds | |
| IL209338A0 (en) | Pharmaceutical compositions containing anti-cd-3 antibodies | |
| MXPA05008688A (es) | Derivados tetraciclicos de pirazol como inhibidores de la cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden. | |
| MXPA04010307A (es) | Derivados 5-oxo y 5-tio de 5h-indeno`1,2-bipiridina con enlace al receptor a2a de la adenosina y actividad inhibidora de la fosfodiesterasa para el tratamiento de trastornos neurodegenerativos y enfermedades relacionadas con la inflamacion. | |
| WO2004099388A3 (en) | Cbl-b polypeptides, complexes and related methods | |
| IL163951A (en) | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | |
| MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
| WO2004069160A3 (en) | Chemical compounds | |
| WO2002068476A3 (en) | Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders | |
| WO2007146602A8 (en) | Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use | |
| WO2005054172A3 (en) | Jasmonate derivative compounds, pharmaceuticals compositions and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |